Long Term Improvements in Patients with Chronic Fatigue Syndrome Treated with Ampligen

References

• Haines DS, Strauss KI, and Gillespie DH. Cellular response to double-stranded RNA. J Cell Biochem. 1991; 46:9–20.
   PubMed Web of Science ®Google Scholar
• Strayer DR, Brodsky I, Pequignot EC et al. The antitumor activity of Ampligen, a mismatched double-stranded RNA that modulates the 2-5A synthe-tase/RNase L pathway in cancer and AIDS. In: Diasio RB and Somrnadossi J-P, eds. Advances in the Chemotherapy of AIDS, New York: Pergamon Press, 1990; 23–31.
   Google Scholar
• Carter WA, Pitha PM, Marshall LW et al. Structural requirements of the rIn:ren complex for induction of human interferon. J Mol Biol. 1972; 70:567–87.
   PubMed Web of Science ®Google Scholar
• Lepe-Zuniga JL, Rotbein J, and Gutterman JU. Production of interferon-a induced by dsRNA in human peripheral blood mononuclear cell cultures: role of priming by dsRNA-induced interferons-y and -13. J Interferon Res. 1989; 9:445–56.
   Google Scholar
• Mémet S, Besancon F, Bourgeade M-F, and Thang MN. Direct induction of interferon-y- and interferon-a/13-inducible genes by double-stranded RNA. J Interferon Res. 1991; 11:131–41.
   Google Scholar
• Garfinkel S, Haines DS, Brown S et al. Interleulcin-la mediates an alterna-tive pathway for the antiproliferative action of poly(I:C) on human endothelial cells. JBiol Chem. 1992; 267:24375–78.
   PubMed Web of Science ®Google Scholar
• Ray A, Tatter SB, May LT, and Sehgal PB. Activation of the human "P2-interferon/hepatocyte-stimu1ating factorfmterleukin 6" promoter by cyto-Icines, viruses, and second messenger agonists. Proc Nail Acad Sci USA. 1988; 85:6701–5.
   Google Scholar
• Remels L, Fransen L, Huygen K, and DeBaetselier PC. Poly I:C activated macrophages are tumoricidal for TNE-a-resistant 3LL tumor cells. J Immunol. 1990; 11:4477–86.
   Google Scholar
• Zullo JN, Cochran BH, Huang AS and Stiles CD. Platelet-derived growth factor and double-stranded ribonucleic acids stimulate expression of the same genes in 3T3 cells. Cell 1985; 43:793–800.
   Google Scholar
• Ushijima H, Rytik PG, Schiicke H et al. Mode of action of the anti-AIDS compound poly (I):poly (C1215)(Ampligene): Activator of 2',5'-oligoadenylate synthetase and double-stranded RNA-dependent kinase. J Interferon Res. 1993; 13:161–71.
   PubMedGoogle Scholar
• Holmes GP, Kaplan JE, Gantz NM et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med. 1988; 108:387–9.
   PubMed Web of Science ®Google Scholar
• Holmes GP, Kaplan JE, Stewart JA et al. A cluster of patients with a chronic mononucleosis-like syndrome: is Epstein-Barr virus the cause? JAMA 1987; 257:2297–302.
   PubMed Web of Science ®Google Scholar
• Straus SE. The chronic mononucleosis syndrome. J Infect Dis. 1988; 157:405–12.
   PubMed Web of Science ®Google Scholar
• Josephs SF, Henry B, Balachandran N et al. HHV-6 reactivation in chronic fatigue syndrome. Lancet 1991; 337:1346–7.
   PubMed Web of Science ®Google Scholar
• Buchwald D, Cheney PR, Peterson DL et al. A chronic illness character-ized by fatigue, neurologic and immunologic disorders, and active human herpes-virus type 6 infection. Ann Intern Med. 1992; 116:103–13.
   PubMed Web of Science ®Google Scholar
• Carter WA, Strayer DR, Brodsky I et al. Clinical, immunological, and viro-logical effects of Ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex. Lancet 1987; 1:1286–92.
   PubMed Web of Science ®Google Scholar
• Strayer DR, Carter WA, Pequignot E et al. Activity of a synthetic cisRNA-Ampligen in HIV Disease. Clinical Biotechnology 1991; 3:169–75.
   Google Scholar
• Strauss KI, Strayer DR and Gillespie DR. Detection of poly(I):poly(Cl2U), mismatched-double-stranded RNA, by rapid solution hybridization: blood values after intravenous infusion. J Pharm Pharmacol. 1990; 42:261–6.
   Google Scholar
• Saiahuddin SZ, Ablashi DV, Markham PD et al. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 1986; 234:596–601.
   PubMed Web of Science ®Google Scholar
• Ablashi DV, Zompetta C, Lease C et al. Human herpesvirus-6 (ITHV-6) and chronic fatigue syndrome (CFS). Can Dis Wkly Rep. 1991; 17(suppl):33–7.
   Google Scholar
• Balachandran N, Amelse RE, Zhou WW and Chang CK. Identification of proteins specific for human herpesvirus 6-infected human T cells. J Viol. 1989; 63:2835–40.
   Google Scholar
• Bastien S. Patterns of Neuropsychological Abnormalities and Cognitive Impairment in Adults and Children. In: Hyde, B. ed. The Clinical and Scientific Basis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Ottawa: Canada: The Nightingale Research Foundation, 1992, pp. 453–66.
   Google Scholar
• Daugherty SA, Henry BE, Peterson DL et al. Chronic Fatigue Syndrome in Northern Nevada. Reviews Infect Dis. 1991; 13(Suppi. 1):S39–44.
   Google Scholar
• Russell EW. A multiple scoring method for the assessment of complex memory functions. J of Consulting and Clinical Psychology 1975; 43:800–9.
   Web of Science ®Google Scholar
• Osborne D and Davis U. Standard scores for Wechsler memory scale sub-tests. J Clin Psychol. 1978; 34:115–6.
   Google Scholar
• Derogatis LR. SCL-90-R administration, scoring and procedures manual II. Clinical Psychometric Research, Towson, MD, 1983.
   Google Scholar
• Suhadolnik RJ, Reichenbach NL, Hitzges P et al. Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis. 1994; 18(suppl):S96–104.
   Google Scholar
• Straus SE, Dale JK, Tobi M et al. Acyclovir treatment of the chronic fatigue syndrome, lack of efficacy in a placebo-controlled trial. N Engl .1 Med. 1988; 319:1692–8.
   PubMed Web of Science ®Google Scholar
• Behan PO, Behan WWI, and Horrobin D. Effect of high doses of essential fatty acids on the postviral fatigue syndrome. Acta Neurol Scand. 1990; 82:209–16.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Hiclde I, Wakefield D et al. A double-blind, placebo-controlled trial of intravenous inununoglobin therapy in patients with chronic fatigue syn-drome. Am J Med. 1990; 89:561–8.
   PubMed Web of Science ®Google Scholar
• Cox IM, Campbell MJ, and Dowson D. Red blood cell magnesium and chronic fatigue syndrome. Lancet 1991; 337:757–60.
   Google Scholar
• Strayer DR, Carter WA, Brodsky I et al. A controlled clinical trial with a specifically configured RNA drug, poly (I):poly (C12U), in chronic fatigue syn-drome. Clin Infect Dis. 1994; 18(suppl):S88–95.
   Google Scholar
• Ablashi DV, Bernernan DI, Williams M et al. Ampligen inhibits human herpesvirus-6 in vitro. In Vivo, 1994; in press.
   Google Scholar
• Suhadolnik RJ, Reichenbach NL, Hitzges P et al. Changes in the 2-5A syn-thetase/RNase L antiviral pathway in a controlled clinical trial with poly (1):poly (Cull) in chronic fatigue syndrome. In Vivo, 1994; in press.
   Google Scholar